Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.810
+0.190 (5.25%)
At close: Aug 25, 2026, 4:00 PM EDT
3.880
+0.070 (1.84%)
After-hours: Aug 25, 2026, 4:51 PM EDT

SAB Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-12.7813.27-34.11-42.19-18.74-17.14
Depreciation & Amortization
3.123.084.793.753.291.65
Other Amortization
0.260.26----
Loss (Gain) From Sale of Assets
---0.04-0.02-0.01
Loss (Gain) From Sale of Investments
-0.07-0.07----
Stock-Based Compensation
16.685.212.942.422.672.31
Other Operating Activities
-56.63-62.84-5.628.53-10.433.49
Change in Accounts Receivable
---5.562.4512.56
Change in Accounts Payable
1.451.480.92-2.7-0.78-2.94
Change in Unearned Revenue
---1.321.32-0.1-
Change in Other Net Operating Assets
-5.96-5.17-1.9-1.85-1.812.06
Operating Cash Flow
-53.94-44.78-34.29-25.12-23.461.99
Operating Cash Flow Growth
------80.14%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3.5-0.93-0.34-0.2-2.17-10.94
Sale of Property, Plant & Equipment
00-0.040.08-
Investment in Securities
-198.61-120.77-11.63---
Investing Cash Flow
-202.11-121.71-11.96-0.15-2.09-10.94

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--0.520.771.242.84
Long-Term Debt Repaid
--0.42-1.42-1.16-2.42-1.3
Total Debt Repaid
-0.15-0.42-1.42-1.16-2.42-1.3
Net Debt Issued (Repaid)
-0.15-0.42-0.91-0.39-1.191.54
Issuance of Common Stock
261.1168.730.0259.667.760.01
Repurchase of Common Stock
-0.02-0.01-0.02---
Other Financing Activities
-0-0-0.26--5.5234.34
Financing Cash Flow
260.93168.3-1.1766.771.0535.89

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.31-0.21-0.240.02--
Net Cash Flow
4.581.6-47.6741.52-24.526.93

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-57.44-45.71-34.63-25.32-25.63-8.96
Free Cash Flow Growth
------
Free Cash Flow Margin
---2618.65%-1130.71%-107.20%-14.71%
Free Cash Flow Per Share
-1.20-0.74-3.74-4.58-5.89-3.28
Levered Free Cash Flow
-28.84-21.99-22.1-17.95-14.293.28
Unlevered Free Cash Flow
-28.96-22.1-21.91-17.75-14.13.46

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.230.240.370.250.29-
Cash Income Tax Paid
----0.03-
Change in Working Capital
-4.51-3.69-2.32.33-0.2411.68
SEC Filings: 10-K · 10-Q